CytomX Therapeutics (CTMX) Accounts Payables (2014 - 2026)

CytomX Therapeutics has reported Accounts Payables for 13 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 395.65% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 395.65% YoY), and the FY2025 full-year result was $1.3 million, up 19.58% from the prior year.
• Accounts Payables for Q1 2026 stood at $1.4 million, up from $1.3 million in the prior quarter.
• The five-year high for Accounts Payables was $5.2 million in Q3 2022, with the low at $227000.0 in Q2 2025.
• Historically, Accounts Payables has averaged $1.6 million across 5 years, with a median of $1.4 million in 2024.
• Annual changes were most pronounced in 2025 — Accounts Payables slumped 85.95% — and 2026, when it surged 395.65%.
• CytomX Therapeutics' Accounts Payables stood at $2.8 million in 2022, then tumbled by 48.1% to $1.5 million in 2023, then slipped by 25.38% to $1.1 million in 2024, then rose by 19.58% to $1.3 million in 2025, then advanced by 5.15% to $1.4 million in 2026.
• The last three Accounts Payables figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $646000.0 (Q3 2025), per Business Quant data.